The New Hampshire state senate last week passed a bill to bar certain 340B-specific pharmacy benefit manager (PBM) and payer [...] …
Month: March 2024
Two powerful Minnesota state lawmakers have introduced companion bills to expand the state’s existing 340B provider reporting requirements and add [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The West Virginia House today overwhelmingly passed a law to bar drugmaker 340B contract pharmacy restrictions in the state, a [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Multiple conservative media outlets have recently reported that Virginia Republican voters oppose efforts to strengthen the 340B program, as Gov. [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Influential Rhode Island state lawmakers this week introduced companion bills to prohibit drugmaker 340B contract pharmacy restrictions and bar certain [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
The world of 340B has been in a state of dynamic change for several years. The covered entities navigating it with the most success have comprehensive pharmacy strategies. This helps them maximize both the value of their participation and the opportunities provided by
…
The South Dakota governor this week signed legislation to expand on a previous 2019 state law that prohibits certain 340B-specific [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The drugmakers that sued to block Louisiana’s 340B contract pharmacy law “want to have their cake and eat it too,” [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Massachusetts will soon change its Medicaid payment policy to bar managed care plans from paying for seven high-cost, anti-obesity medications [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Drugmaker Genentech announced multi-year refunds to 340B providers on past purchases of two separate high-selling drugs, while Merck offered a [...] …
